arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

Anbio Biotechnology

NNNN

$10.12 ▲ +0.18 (+1.86%) at close

4 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Good

Bullish

auto_awesome

Analytical Summary

Anbio Biotechnology shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $442.0M

Dividend Yield —

Revenue Growth 5.6% ↘

Op. Margin 66.7% ↗

ROIC 19.1% ↗

FCF / Share $-0.15 ↘

Trailing P/E 68.8x

Price / Book 14.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$8.65M

↑ +5.6% —

Net Income Profit after all expenses

$6.40M

↑ +169.9% —

Operating Margin Operating profit as % of sales

66.7%

↑ +173.6% 99th

FCF / Share Free cash flow per share

$-0.15

↓ -413.7% —

trending_up

Bullish Indicators

Operating Margin (%)Operating Margin (%) is in the top quartile
Profit Margin (%)Profit Margin (%) is in the top quartile
Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Profitability ↑

Returns ↓

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Revenue Growth YoY (%)	5.6% Fair ↑ Fair Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-29%)	21.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+174%)	-71.5% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-994%)	—
EPS Growth YoY (%)	162.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-46.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-100.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—
Net Income Growth YoY (%)	169.9% Excellent ↑ Excellent Improving Year-over-year change in net income	5.3% Fair Fair Year-over-year change in net income	-77.5% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	N/M	17.4% Good Good Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	-28.4% Weak Weak Compound annual revenue growth over 3 years	—	—	—
EPS CAGR 3Y (%)	-98.9% Weak Weak Compound annual EPS growth over 3 years	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Operating Margin (%) (%)	66.7% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+345%)	24.4% Good ↓ Good Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+63%)	29.2% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+95%)	43.3% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+189%)
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	74.1% Excellent ↑ Excellent Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+517%)	29.0% Excellent ↓ Excellent Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+142%)	33.6% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+180%)	42.5% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+254%)
FCF Margin (%) (%)	-77.9% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	25.4% Excellent ↑ Excellent Improving Free cash flow as a percentage of revenue Optimal: > 10%	13.4% Fair Fair Free cash flow as a percentage of revenue Optimal: > 10%	18.9% Good Good Free cash flow as a percentage of revenue Optimal: > 10%
FCF / Net Income (x)	-1.05x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.40x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.44x Weak Weak Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Return on Invested Capital (%)	19.1% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	11.6% Good ↓ Good Declining Return earned on debt + equity capital invested Optimal: > 10%	10.5% Good Good Return earned on debt + equity capital invested Optimal: > 10%	64.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%
Return on Capital (%) (%)	19.1% Excellent ↑ Excellent Improving Operating profit relative to total assets Optimal: > 10%	10.5% Good Good Operating profit relative to total assets Optimal: > 10%	12.4% Good Good Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	21.2% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+42%)	13.8% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-8%)	15.2% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: At sector avg	79.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+432%)

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Net Debt (USD)	$-7.77M	$-11.76M	$-9.69M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Revenue per Share (USD)	$0.20	$0.19	$0.31	—
Basic EPS, GAAP (USD)	$0.15	$0.06	$0.10	$100.11K
Free Cash Flow per Share (USD)	$-0.15	$0.05	$0.04	—
Book Value per Share (USD)	$0.69	$0.41	$0.69	—
Tangible Book Value per Share (USD)	$0.69	$0.41	$0.69	—
Basic Weighted Avg Shares (shares)	43.67M	42.29M	21.44M	100

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Working Capital (USD)	$30.16M	$16.80M	$14.76M	—
Total Equity (USD)	$30.16M	$17.19M	$14.82M	$12.55M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Sales/Revenue/Turnover (USD)	$8.65M	$8.19M	$6.71M	$23.54M
Net Income, GAAP (USD)	$6.40M	$2.37M	$2.25M	$10.01M
Operating Cash Flow (USD)	$-6.74M	$2.08M	$898.37K	$4.45M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 4 quarters

Anbio Biotechnology

Analytical Summary

4-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NNNN with peers